Treatment of Secondary Polycythemia in Chronic Obstructive Pulmonary Disease (COPD) with Erythrocytosis
Clinical Scenario
This protocol addresses secondary polycythemia arising in the setting of chronic obstructive pulmonary disease (COPD), specifically where erythrocytosis is present with a haematocrit above 0.55. Erythrocytosis can be associated with advanced COPD, and the incidence — typically defined as haematocrit above 0.55 — ranges from 6 to 8% in this population.
Key Clinical Context
The underlying driver in this scenario is hypoxia from chronic obstructive pulmonary disease. The elevated haematocrit reflects a compensatory response to impaired oxygenation rather than a primary bone marrow process. Identifying and addressing the respiratory cause is central to management.
Treatment Approach (Partial Overview)
Management centres on evaluation by a respiratory physician for methods of improving oxygenation — including consideration of long-term oxygen therapy. Smoking cessation is strongly advised for patients who smoke. The full structured regimen, including all recommended interventions and decision points, is available via the protocol link below.
Treatment Goal
Reduction of the haematocrit through treatment of the underlying hypoxia.
References
DOI: 10.1111/bjh.15647
- Erythrocytosis can be associated with advanced chronic obstructive pulmonary disease (COPD) and with obstructive sleep apnoea syndrome (OSA).
- In COPD, the incidence of erythrocytosis, usually defined as Hct > 0.55, ranges from 6 to 8%.
- All patients with erythrocytosis consequent upon hypoxic pulmonary disease should therefore be evaluated by a respiratory physician for consideration of long-term oxygen therapy or alternative methods of improving oxygenation.
- If they are smokers they should be strongly advised to stop.
- In addition to supplemental oxygen, nocturnal oxygenation may also be improved by the use of non-invasive ventilation.
- Treatment of the underlying hypoxia reduces the Hct.
View source ↗